Stephen M. Gollomp

Stephen M. Gollomp

Neurology

100 East Lancaster Avenue
Lankenau Med Blgd East Suite 161
Wynnewood, PA 19096

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics.

Mitigating Immunogenicity by Coordinating Botulinum Toxin Treatments Between Aesthetics and Therapeutics.

Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]

Published: August 28, 2024

A Narrative Literature Review of the Established Safety of Human Serum Albumin Use as a Stabilizer in Aesthetic Botulinum Toxin Formulations Compared to Alternatives.

A Narrative Literature Review of the Established Safety of Human Serum Albumin Use as a Stabilizer in Aesthetic Botulinum Toxin Formulations Compared to Alternatives.

Journal: Toxins

Published: August 11, 2023

GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding.

Journal: Journal of the neurological sciences

Published: April 25, 2015

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.

Journal: Journal of neural transmission (Vienna, Austria : 1996)

Published: December 05, 2012

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Journal: Journal of the neurological sciences

Published: August 29, 2012

Showing 1-5 of 5

Last Updated: 09/26/2026